Core Viewpoint - Dividend investing can build wealth and provide passive income, with dividend stocks outperforming non-dividend payers in the long run [1] Group 1: Dividend Stocks Overview - Dividend stocks can be ideal long-term investments even for those focused on growth stocks, as they provide stability during market fluctuations [2] - Companies that are essential in their industries and offer in-demand products and services are key targets for dividend investing [2] Group 2: Verizon Communications - Verizon is a leading telecom company in the U.S. with over 146 million wireless customers, playing a significant role in the economy [4] - The company is expanding its broadband business and plans to add over 2.2 million new fiber subscribers through the acquisition of Frontier Communications [5] - Verizon's stock has a yield of 7.01%, a payout ratio of 57.68%, and has raised dividends for 21 consecutive years, paying an annual dividend of $2.76 per share [5] - Despite recent struggles in gaining new wireless customers, Verizon is viewed as a long-term stability and dividend investment opportunity [7] Group 3: Johnson & Johnson - Johnson & Johnson is now a pure-play health company focusing on medical technology and innovative drugs, operating in a non-cyclical industry [8] - The stock has a yield of 2.37%, priced at $219.57, and has gained 48% over the past year [9] - The company reported a 4.4% year-over-year revenue increase and a 15.7% EPS jump in the third quarter, generating $14.3 billion in free cash flow in the first nine months of 2025 [10] - Johnson & Johnson has a payout ratio of 48.94%, has increased dividends for 63 years, and pays an annual dividend of $5.20 per share with a 5-year dividend growth rate of 5.25% [12] Group 4: Coca-Cola - Coca-Cola is a blue-chip dividend stock with a yield of 2.89%, having raised dividends for 63 consecutive years [13] - The stock is priced at $70.48, with a 13% gain over the past year, and has a payout ratio of 67.85%, paying an annual dividend of $2.04 per share [14] - Coca-Cola operates an asset-light business model, selling concentrates and syrups to bottling partners, which minimizes operating costs and generates steady revenue [15] - The company has demonstrated resilience, generating over 100% total return over the past decade, making it a reliable choice for dividend investors [16]

PresentationGood morning, everybody. I'm David Adlington. I head up the research group for JPMorgan in London for Medical Devices and Services. It's my pleasure this morning to introduce Michael Sen from Fresenius SE, and then we'll follow up the presentation with some Q&A. Michael, thank you very much.Michael SenCEO, President & Chairman of Management Board of Fresenius Management SE So good morning, everybody, and thank you, David. Thanks for having us. I think it's a wonderful opportunity to come togethe ...

Core Points - The U.S. has agreed to remove Section 232 tariffs on pharmaceutical goods from the U.K. as part of a new agreement [1] - The deal includes U.K.-based pharmaceuticals, pharmaceutical ingredients, and medical technology, with no future targeting of U.K. pricing practices during Trump's term [2] - The tariff exemption is contingent upon the U.K. reversing declining National Health Service expenditures on medicines and increasing the net price paid for new medicines by 25% [3] - This announcement is part of the U.S.-U.K. Economic Prosperity Deal framework, which aims to address tariffs and market access, with the potential for the U.K. to reduce tariffs on U.S. goods from 5.1% to 1.8% [4] - Trump has been focusing on pharmaceutical imports as part of a sector-specific tariff strategy, with a Section 232 investigation initiated in April [5] - Plans for a 100% sector-specific tariff on branded or patented pharmaceutical products were announced in September, alongside a probe into healthcare-related products [6]